Every SEC filing alert our engine sent, newest first: 8-K material events, deals, capital raises, leadership changes, results and insider buying and selling.
Neptune Insurance Holdings President & Chief Risk Officer Matthew Paul Duffy Sells $1.12M of Stock
Matthew Paul Duffy, President & Chief Risk Officer, sold 41,392 shares of Neptune Insurance Holdings Inc. at $27.15 a share, worth $1.12M in total on Oct 6, 2026. Shares held after the trade: 1,964,239 (-2.1%).
Atkore Inc. stockholders approved the adoption of the previously announced merger agreement with Prysmian S.p.A. at a special meeting held on October 7, 2026. Approximately 81.84% of outstanding shares were represented, with the merger proposal receiving overwhelming support (over 27.6 million votes in favor). Upon completion, Atkore will become a wholly owned subsidiary of Prysmian.
Castle Biosciences Pres. & Chief Exec. Officer Derek J. Maetzold Sells $516K of Stock
Derek J. Maetzold, Pres. & Chief Exec. Officer, sold 14,496 shares of Castle Biosciences Inc at $35.57 a share, worth $516K in total on Oct 5, 2026. Shares held after the trade: 6,832 (-28.5%).
Immersion Corporation held its fiscal year 2026 Annual Meeting of Stockholders on October 7, 2026. Shareholders elected five directors to serve until the 2027 annual meeting, ratified BDO USA, P.C. as the independent accounting firm for fiscal 2027, and approved executive compensation in an advisory vote.
Blend Labs Head of Blend Nima Ghamsari Sells $24.7K of Stock
Nima Ghamsari, Head of Blend, sold 24,272 shares of Blend Labs, Inc. at $1.02 a share, worth $24.7K in total on Oct 5, 2026. Shares held after the trade: 7,803,566 (-0.3%).
Capital One Financial General Counsel & Corp Secy Matthew W. Cooper Sells $687K of Stock
Matthew W. Cooper, General Counsel & Corp Secy, sold 3,500 shares of Capital One Financial Corp at $196.22 a share, worth $687K in total on Oct 6, 2026. Shares held after the trade: 79,694 (-4.2%).
Vaxcyte EVP, Chief Scientific Ofc, COO Jim Wassil Sells $1.56M of Stock
Jim Wassil, EVP, Chief Scientific Ofc, COO, sold 18,000 shares of Vaxcyte, Inc. at $86.74 a share, worth $1.56M in total on Oct 5, 2026. Shares held after the trade: 145,435 (-11.0%).
Vaxcyte SVP, Finance & CAO Elvia Cowan Sells $1.65M of Stock
Elvia Cowan, SVP, Finance & CAO, sold 19,000 shares of Vaxcyte, Inc. at $86.74 a share, worth $1.65M in total on Oct 5, 2026. Shares held after the trade: 27,860 (-40.5%).
Finance of America Companies Chief Investment Officer Jeremy Prahm Sells $79.2K of Stock
Jeremy Prahm, Chief Investment Officer, sold 6,000 shares of Finance of America Companies Inc. at $13.20 a share, worth $79.2K in total on Oct 5, 2026. Shares held after the trade: 155,856 (-3.7%).
John T. Hall, CEO, sold 3,000 shares of Intapp, Inc. at $36.50 a share, worth $110K in total on Oct 5, 2026. Shares held after the trade: 5,814,808 (-0.1%).
Progress Software CLO Yufan Stephanie Wang Sells $46.1K of Stock
Yufan Stephanie Wang, CLO, sold 1,245 shares of Progress Software Corp at $37.00 a share, worth $46.1K in total on Oct 5, 2026. Shares held after the trade: 3,487 (-26.3%).
Resources Connection, Inc. (RGP) reported first quarter fiscal 2027 revenue of $98.1 million, an 18.4% decrease on a same-day constant currency basis compared to the prior year. The company reported a net loss of $8.0 million ($0.23 per diluted share) as results were impacted by lower project volume and utilization in its Consulting segment.
Term
Q1 2027
“Our first-quarter results were within the revenue and gross margin ranges we communicated in July, with adjusted SG&A expense better than our outlook. However, our revenue and profitability remained below our potential, driven primarily by lower project volume and utilization in Consulting and ongoing caution in client decision-making.”
Roger Carlile, President and Chief Executive Officer
“We remain confident in the long-term demand for RGP’s integrated model, which combines on-demand talent, consulting, and managed services to help clients move from strategy to execution. Our focus is on translating that differentiated model into more consistent revenue growth, improved utilization, and stronger profitability.”
Roger Carlile, President and Chief Executive Officer
Riley Exploration Permian $130M Debt Financing with Truist Bank
Riley Exploration Permian, Inc. borrowed $130 million under its existing credit facility with Truist Bank to voluntarily prepay in full its 10.50% Senior Unsecured Notes due 2028. The refinancing leaves the company's total debt substantially unchanged while satisfying and discharging all obligations under the previous Note Purchase Agreement.
MicroVision held a virtual business update event to reaffirm its 2026 revenue guidance of $10 million to $15 million and project a doubling of revenue in 2027. Management outlined a 'Lidar 2.0' strategy focused on commercial execution across industrial, defense, and AI data center markets while planning a significant reduction in cash burn for 2027.
Advasa Holdings appointed William Witherspoon as its new Chief Financial Officer, effective October 6, 2026. Mr. Witherspoon, who previously served as an independent director, will receive an annual base salary of $200,000 and is eligible for discretionary bonuses and equity grants. He succeeds CEO Grady Ryther, who had been serving as interim CFO since August 2026.
Medicus Pharma Ltd. announced a fifty-to-one (1-for-50) reverse stock split of its common shares effective October 12, 2026. The consolidation is intended to increase the per-share bid price to regain compliance with Nasdaq's minimum bid price requirement for continued listing. The split was previously authorized by shareholders at the company's annual meeting on June 3, 2026.
Ocean Power Technologies announced that Robert Powers departed as CFO effective September 30, 2026, and will remain through October 14, 2026, to assist with the transition. The company has appointed Victoria Hay from Flexible Consulting, LLC as interim Chief Financial Officer while conducting a search for a permanent successor. Mr. Powers will receive six months of base salary and his fiscal 2026 bonus as part of a severance agreement.
Unusual Machines, Inc. held its 2026 Annual Meeting of Stockholders on October 5, 2026, where shareholders elected five directors and ratified Ernst & Young LLP as the independent auditor for the fiscal year ending December 31, 2026. Stockholders also approved a warrant grant to the company's Chief Executive Officer and an adjournment proposal, though adjournment was not necessary as all primary proposals passed.
Matternet, Inc. entered into a separation agreement with outgoing Chief Financial Officer Jason Secore, whose employment ended on September 29, 2026. Under the agreement, Mr. Secore will receive a cash payment of $156,146 and an extension of the post-termination exercise period for his equity awards. CEO Andreas Raptopoulos is currently serving as the interim CFO while the company searches for a permanent successor.
Twist Bioscience CEO Emily M. Leproust Sells $910K of Stock
Emily M. Leproust, CEO, sold 4,503 shares of Twist Bioscience Corp at $200.44 to $206.84 a share (average $202.10) in 7 transactions, worth $910K in total on Oct 5, 2026. Shares held after the trade: 562,805 (-0.0%).
Applied Optoelectronics *** See Remarks Shu-Hua (Joshua) Yeh Sells $720K of Stock
Shu-Hua (Joshua) Yeh, *** See Remarks, sold 6,000 shares of Applied Optoelectronics, Inc. at $120.03 a share, worth $720K in total on Oct 5, 2026. Shares held after the trade: 371,498 (-1.6%).
SOPHiA Genetics Chief People Officer Manuela Valente Sells $34.5K of Stock
Manuela Valente, Chief People Officer, sold 4,240 shares of SOPHiA Genetics SA at $8.13 a share, worth $34.5K in total on Oct 5, 2026. Shares held after the trade: 206,210 (-2.0%).
SOPHiA Genetics CLO Well Daan Van Sells $50.1K of Stock
Well Daan Van, CLO, sold 6,168 shares of SOPHiA Genetics SA at $8.12 a share, worth $50.1K in total on Oct 5, 2026. Shares held after the trade: 332,716 (-1.8%).
SOPHiA Genetics CTO Abhimanyu Verma Sells $42.9K of Stock
Abhimanyu Verma, CTO, sold 5,284 shares of SOPHiA Genetics SA at $8.12 a share, worth $42.9K in total on Oct 5, 2026. Shares held after the trade: 166,887 (-3.1%).
SOPHiA Genetics CMO Philippe Menu Sells $60.1K of Stock
Philippe Menu, CMO, sold 7,394 shares of SOPHiA Genetics SA at $8.13 a share, worth $60.1K in total on Oct 5, 2026. Shares held after the trade: 200,993 (-3.5%).
SOPHiA Genetics CFO George Cardoza Sells $12.9K of Stock
George Cardoza, CFO, sold 1,592 shares of SOPHiA Genetics SA at $8.10 a share, worth $12.9K in total on Oct 5, 2026. Shares held after the trade: 306,726 (-0.5%).
SOPHiA Genetics Executive Chairman Jurgi Camblong Sells $327K of Stock
Jurgi Camblong, Executive Chairman, sold 40,172 shares of SOPHiA Genetics SA at $8.13 a share, worth $327K in total on Oct 5, 2026. Shares held after the trade: 3,395,650 (-1.2%).
SOPHiA Genetics CEO Ross Muken Sells $80K of Stock
Ross Muken, CEO, sold 9,838 shares of SOPHiA Genetics SA at $8.13 a share, worth $80K in total on Oct 5, 2026. Shares held after the trade: 660,391 (-1.5%).
SOPHiA Genetics CSO Zhenyu Xu Sells $60.1K of Stock
Zhenyu Xu, CSO, sold 7,394 shares of SOPHiA Genetics SA at $8.12 a share, worth $60.1K in total on Oct 5, 2026. Shares held after the trade: 545,493 (-1.3%).
Artiva Biotherapeutics CEO Fred Aslan Sells $169K of Stock
Fred Aslan, CEO, sold 23,463 shares of Artiva Biotherapeutics, Inc. at $7.20 a share, worth $169K in total on Oct 6, 2026. Shares held after the trade: 1,519,606 (-1.5%).